Latest / Cell & Gene: The Podcast

What Changes to FDA and CBER Mean for the Future of CGT with Daniela Drago
We love to hear from our listeners. Send us a message.
This is Episode 4 of "FDA Fridays," a special series from Cell & Gene: The Podcast, Chief Editor Erin Harris speaks with regulatory affairs expert Daniela Drago, Partner, NDA Partners, about how shifting FDA and CBER priorities under the current administration could influence the trajectory of cell and gene therapy development. From the impact of leadership changes and evolving policy directives to the role of funding allocations and public health priorities, Drago sheds light on what CGT developers and sponsors should be watching most…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.